New Population Health Approach to Secondary Prevention for ASCVD Framework and Infographic Released

Alexandria, VA – AMGA Foundation has released the “Population Health Approach to Secondary Prevention for ASCVD Framework and Infographic,” a primer for implementing proven strategies to improve the management and treatment of patients with established atherosclerotic cardiovascular disease (ASCVD). AMGA collaborated with 12 high-performing healthcare organizations (HCOs) to develop a framework of care for patients with established ASCVD. 

The framework and infographic highlight practical and actionable interventions that have been tested and proven by the 12 organizations that participated in AMGA Foundation’s ASCVD Best Practices Learning Collaborative. 

“ASCVD is a major contributor to cardiovascular disease, the leading cause of death in the United States. Collaborative participating groups made great progress in implementing interventions identified for successful patient care in secondary prevention of ASCVD. The groups’ important work improved their own patient care and have a broader impact as we make the best practices available to all,” said John Kennedy, MD, AMGA Foundation president and AMGA chief medical officer. “Using these learnings and applying a population health approach, we can contribute to improved care for millions of patients living with ASCVD.”  

The infographic contains motivating needs, important or essential aspects to successful patient care in secondary prevention for ASCVD. HCOs developed and implemented interventions to address each motivating need, including:

• Knowledge (provider/staff) about patients’ need for secondary prevention for ASCVD
• Incorporate clinical decision support tools within the electronic health record (EHR) for compliance and follow-up
• Identify a disparate patient population (e.g., race/ethnicity, gender, ZIP code, and income) who have gaps in care
• Provide a team-based approach for integration of services 
• Patient awareness and education about secondary prevention for ASCVD

A peer reviewed journal article detailing the impact of a Best Practices Learning Collaborative to improve the management of patients with ASCVD for secondary prevention is also available on the website.

“Novartis proudly supports the AMGA Foundation and the participating Health Care Organization’s efforts in improving patient care and outcomes in ASCVD - a major contributor to cardiovascular disease, the leading cause of death in the US,” said Cesar Cerezo, VP, Medical Head at Novartis Pharmaceuticals Corporation. "Collaborating with patients, healthcare providers, and organizations can enhance cardiovascular care beyond medicines. Up to 80% of ASCVD patients do not reach target LDL-C levels on statins alone due to poor medication adherence. Population health initiatives focused on better lipid-lowering treatment management and adherence can create significant and sustainable improvements." 

“Every 40 seconds, someone in the U.S. has a heart attack or stroke and high LDL-C, or ‘bad’ cholesterol, is one of the most important factors that can be controlled to reduce the risk of these events,” said Leandro Boer, MD, VP U.S. Medical and General Medicine Therapeutic Head at Amgen. “Sharing best practices and learnings is essential to advancing patient care and improving outcomes for individuals with ASCVD. Through supporting initiatives like AMGA’s collaborative framework, Amgen is reinforcing our commitment to programs that increase providers’ access to the proven strategies that address care gaps, improve lipid management and support effective secondary prevention efforts.” 

About ASCVD Best Practices Learning Collaborative
The ASCVD Collaborative, supported by Novartis Pharmaceuticals Corporation and Amgen, began in 2022 to help medical groups develop strategies to improve the management and treatment of patients with atherosclerotic cardiovascular disease (ASCVD). During the collaborative, 12 healthcare organizations identified innovations, successes, and challenges to address the management and treatment of ASCVD. Two national organizations, National Forum for Heart Disease and Stroke Prevention and WomenHeart, participated as collaborators and resources to the participants. By the end of the Collaborative, HCOs demonstrated improvement in one or more Collaborative measure. More information about this collaborative, including a peer-reviewed journal article, is available on AMGA’s website. 

###

About AMGA Foundation

AMGA Foundation is AMGA’s philanthropic arm that enables medical groups and other organized systems of care to consistently improve health and healthcare. AMGA Foundation serves as a catalyst, connector, and collaborator for translating the evidence of what works best in improving health and health care in everyday practice. Learn more at amga.org/foundation.

About AMGA

AMGA is a trade association leading the transformation of healthcare in America. Representing multispecialty medical groups and integrated systems of care, we advocate, educate, innovate, and empower our members to deliver the next level of high performance health. AMGA is the national voice promoting awareness of our members’ recognized excellence in the delivery of coordinated, high-quality, high-value care. More than 175,000 physicians practice in our member organizations, delivering care to one in three Americans. 

AMGA represents medical groups and integrated systems of care. Its diverse membership includes multispecialty medical groups, integrated delivery systems, accountable care organizations, and other entities committed to improving healthcare outcomes. AMGA advocates for the formation of innovative, clinically integrated systems of care that advance population health, enhance patient experience, and reduce healthcare costs. For more information, please visit www.amga.org.